A new alliance with the collaboration for the clinical trials in oncology means that the Kazia Therapeutics will soon be having 4 clinical trials of GDC-0084 ongoing in either primary or secondary brain cancers.
There has been an identification of a higher max tolerated dose by Kazia Therapeutics from 2nd phase study of brain-penetrant phosphoinositide 3-kinase inhibitor GDC-0084 in glioblastoma, which might lead to better efficacy in the underway expansion cohort & planned 2nd phase study
Glioblastoma multiforme is the most usual and destructive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in 1/3 of patients.
In addition to this, the average survival rate is 12 to 15 months from diagnosis, implying that there is a demand in the market for higher treatments.
A suggestive valuation range has been assigned by the Edison Investment Research of $84 million to $135 million or $1.35 million to $2.17 million per share for Kazia Therapeutics.
Extract on Kazia from Edison’s pipeline update is as follows:
Kazia Therapeutics is an Australia-based biotech firm which is focused on the development of oncology drug.
It is creating GDC-0084, which is a brain-penetrant PI3K inhibitor certified from Genentech, and Cantrixil which is a 3rd generation benzopyran drug.
It is also anticipating further initial efficacy data from its Cantrixil Phase 1 study in ovarian cancer.
Kazia’s Phase 1 study indicated that lately diagnosed Glioblastoma patients were able to bear a higher and hence potentially more effective dose of its oral PI3K inhibitor GDC-0084 than Genentech had reported from its prior study in patients with late-stage disease. A 20-patient expansion cohort is expected to report top-line efficacy data in the last quarter of this year.
The Glioblastoma trials will be testing GDC-0084 in patients who have an unmethylated MGMT promoter.